Author: Mitchell Gaydash
03 Jun Webinar : Use of Non-animal Skin Sensitization Methods
A recorded webinar on the "Use of Non-animal Skin Sensitization Methods" by IIVS’s Hans Raabe and US EPA's Gino Scarano and James Cox is now available for viewing at https://www.piscltd.org.uk/nam-webinars/. The webinar reviews the status of Non-Animal methods acceptance of skin sensitization testing within the...
21 May Services and Tools for COVID-19 Drug Development
IIVS provides robust test systems and assays to detect the adverse effects of diverse materials, including pharmaceuticals targeting COVID-19. The IIVS Respiratory Toxicology Program offers testing services using cutting edge 3D pulmonary models - in addition to human 2D primary cells and lines - such...
06 May Respiratory Toxicology for Pharmaceutical Development
The Institute for In Vitro Sciences (IIVS) provides robust test systems and assays to detect the adverse effects of diverse materials, including pharmaceuticals targeting COVID-19. The IIVS Respiratory Toxicology Program offers testing services using cutting edge 3D pulmonary models - in addition to human 2D...
22 Apr FDA Releases New Guidance Recommending Alternatives to LLNA
FDA releases new guidance recommending the performance of alternative test methodologies in lieu of the murine-based Local Lymph Node Assay (LLNA) to assess skin sensitization potential for topically-applied drug products. This information can be found at https://www.fda.gov/media/135312/download, pages 7-8. IIVS offers multiple assays and provides guidance to...